Table 3 Cox proportional hazards regression for progression-free survival and overall survival of newly diagnosed patients.
Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Age | ≥ 60 versus < 60 | 0.71 (0.43–1.19) | 0.195 | 1.09 (0.52–2.29) | 0.811 |
Sex | Male versus female | 1.57 (0.86–2.88) | 0.141 | 1.48 (0.64–3.39) | 0.359 |
Tumor size | > 3 cm versus < 3 cm | 1.07 (0.47–2.46) | 0.873 | 0.93 (0.26–3.30) | 0.915 |
Nodal involvement | Positive versus negative | 1.65 (0.75–3.60) | 0.212 | 1.81 (0.52–6.30) | 0.354 |
EGFR mutation | Del 19 versus L858R | 0.79 (0.44–1.42) | 0.428 | 1.19 (0.52–2.72) | 0.678 |
Brain metastasis | Presence versus absence | 2.25 (1.06–4.77) | 0.034 | 1.13 (0.35–3.59) | 0.843 |
EGFR-TKI | 2nd generation versus 1st generation EGFR-TKI | 0.63 (0.35–1.12) | 0.113 | 0.62 (0.27–1.40) | 0.250 |
Surgery | With primary tumor resection versus without primary tumor resection | 0.14 (0.07–0.26) | < 0.001 | 0.12 (0.04–0.36) | < 0.001 |
